Cargando…

Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease

INTRODUCTION: We determine whether diminished Learning Over Repeated Exposures (LORE) identifies subtle memory decrements in cognitively unimpaired (CU) older adults with Alzheimer's disease (AD) biomarker burden. METHODS: Ninety‐four CU participants (mean age = 77.6 ± 5.02) completed a challen...

Descripción completa

Detalles Bibliográficos
Autores principales: Samaroo, Aubryn, Amariglio, Rebecca E., Burnham, Samantha, Sparks, Paige, Properzi, Michael, Schultz, Aaron P., Buckley, Rachel, Johnson, Keith A., Sperling, Reisa A., Rentz, Dorene M., Papp, Kathryn V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784542/
https://www.ncbi.nlm.nih.gov/pubmed/33426266
http://dx.doi.org/10.1002/dad2.12132
Descripción
Sumario:INTRODUCTION: We determine whether diminished Learning Over Repeated Exposures (LORE) identifies subtle memory decrements in cognitively unimpaired (CU) older adults with Alzheimer's disease (AD) biomarker burden. METHODS: Ninety‐four CU participants (mean age = 77.6 ± 5.02) completed a challenging associative memory test, at home, monthly, for up to 1 year (mean = 9.97 months) on a study‐issued iPad. Learning curves for face‐name memory were computed for two versions completed monthly: same face‐name pairs (A‐A‐A) and alternate face‐name pairs (B‐C‐D). Positron emission tomography (PET) imaging characterized global amyloid (Pittsburgh Compound‐B (PiB); amyloid beta (Aβ)+/−) and regional tau burden (flortaucipir). RESULTS: Diminished LORE for same (but not alternate) face‐name pairs was associated with greater amyloid and tau burden. Aβ+/− group differences for same face‐name pairs emerged by the fourth exposure and was of medium‐to‐large magnitude (Cohen's d = 0.66; 95% confidence interval [CI] = 0.25‐1.08). DISCUSSION: Subtle decrements in learning related to AD pathological burden in CU are detectable over short time‐intervals (ie, months). Implications for prevention trial design are discussed.